{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:29:46Z","timestamp":1748341786499,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Johns Hopkins University Center of Excellence in Regulatory Science","Innovation"],"award-info":[{"award-number":["Johns Hopkins University Center of Excellence in Regulatory Science","Innovation"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40264-024-01481-x","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:02:30Z","timestamp":1727157750000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug\u2013Drug Interactions Between Immunosuppressants and Cannabis-Derived Products"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6372-9405","authenticated-orcid":false,"given":"Matthew R.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenyth Portillo","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zechariah","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Poliak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Dredze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"unstructured":"Hansen C, Alas H, Davis E. Where Is Marijuana Legal? A Guide to Marijuana Legalization. Available at: https:\/\/www.usnews.com\/news\/best-states\/articles\/where-is-marijuana-legal-a-guide-to-marijuana-legalization. Accessed 9 Mar 2023.","key":"1481_CR1"},{"issue":"11","key":"1481_CR2","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2105\/AJPH.2021.306499","volume":"111","author":"EC Leas","year":"2021","unstructured":"Leas EC. The hemp loophole: a need to clarify the legality of delta-8-THC and other hemp-derived tetrahydrocannabinol compounds. Am J Public Health. 2021;111(11):1927\u201331. https:\/\/doi.org\/10.2105\/AJPH.2021.306499.","journal-title":"Am J Public Health"},{"issue":"22","key":"1481_CR3","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2019.4432","volume":"321","author":"JW Ayers","year":"2019","unstructured":"Ayers JW, Caputi TL, Leas EC. The need for federal regulation of marijuana marketing. JAMA. 2019;321(22):2163. https:\/\/doi.org\/10.1001\/jama.2019.4432.","journal-title":"JAMA"},{"unstructured":"US Food and Drug Administration Office of the Commissioner. FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD)","key":"1481_CR4"},{"issue":"10","key":"1481_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20977","volume":"3","author":"EC Leas","year":"2020","unstructured":"Leas EC, Hendrickson EM, Nobles AL, et al. Self-reported cannabidiol (CBD) use for conditions with proven therapies. JAMA Netw Open. 2020;3(10): e2020977. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20977.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1481_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13853","volume":"2","author":"EC Leas","year":"2019","unstructured":"Leas EC, Nobles AL, Caputi TL, Dredze M, Smith DM, Ayers JW. Trends in internet searches for cannabidiol (CBD) in the United States. JAMA Netw Open. 2019;2(10): e1913853. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.13853.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1481_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47373","volume":"6","author":"AR Wilson-Poe","year":"2023","unstructured":"Wilson-Poe AR, Smith T, Elliott MR, Kruger DJ, Boehnke KF. Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and \u03b48-tetrahydrocannabinol among US adults. JAMA Netw Open. 2023;6(12): e2347373. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.47373.","journal-title":"JAMA Netw Open"},{"unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. Published 4 Jan 2023. Available at: https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report. Accessed 9 Feb 2024.","key":"1481_CR8"},{"issue":"9","key":"1481_CR9","doi-asserted-by":"publisher","first-page":"E206","DOI":"10.1503\/cmaj.191097","volume":"192","author":"T Antoniou","year":"2020","unstructured":"Antoniou T, Bodkin J, Ho JMW. Drug interactions with cannabinoids. Can Med Assoc J. 2020;192(9):E206. https:\/\/doi.org\/10.1503\/cmaj.191097.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"1481_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medicines6010003","volume":"6","author":"M Alsherbiny","year":"2018","unstructured":"Alsherbiny M, Li C. Medicinal cannabis\u2014potential drug interactions. Medicines. 2018;6(1):3. https:\/\/doi.org\/10.3390\/medicines6010003.","journal-title":"Medicines"},{"issue":"33\u201334","key":"1481_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3238\/arztebl.2012.0546","volume":"109","author":"I Cascorbi","year":"2012","unstructured":"Cascorbi I. Drug interactions\u2013principles, examples and clinical consequences. Dtsch Arzteblatt Int. 2012;109(33\u201334):546\u201355. https:\/\/doi.org\/10.3238\/arztebl.2012.0546. (quiz 556).","journal-title":"Dtsch Arzteblatt Int"},{"issue":"5","key":"1481_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40264-023-01283-7","volume":"46","author":"L L\u00e9tinier","year":"2023","unstructured":"L\u00e9tinier L, Bezin J, Jarne A, Pariente A. Drug\u2013drug interactions and the risk of emergency hospitalizations: a nationwide population-based study. Drug Saf. 2023;46(5):449\u201356. https:\/\/doi.org\/10.1007\/s40264-023-01283-7.","journal-title":"Drug Saf"},{"issue":"6","key":"1481_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.31128\/AJGP-02-21-5845","volume":"50","author":"JC Arnold","year":"2021","unstructured":"Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. 2021;50(6):345\u201350. https:\/\/doi.org\/10.31128\/AJGP-02-21-5845.","journal-title":"Aust J Gen Pract."},{"issue":"8","key":"1481_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa1916433","volume":"382","author":"BC Blount","year":"2020","unstructured":"Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med. 2020;382(8):697\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa1916433.","journal-title":"N Engl J Med"},{"issue":"3","key":"1481_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.15585\/mmwr.mm6903e2","volume":"69","author":"VP Krishnasamy","year":"2020","unstructured":"Krishnasamy VP, Hallowell BD, Ko JY, et al. Update: characteristics of a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury\u2014United States, August 2019\u2013January 2020. MMWR Morb Mortal Wkly Rep. 2020;69(3):90\u20134. https:\/\/doi.org\/10.15585\/mmwr.mm6903e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1481_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMp1916171","volume":"382","author":"BA King","year":"2020","unstructured":"King BA, Jones CM, Baldwin GT, Briss PA. The EVALI and youth vaping epidemics\u2014implications for public health. N Engl J Med. 2020;382(8):689\u201391. https:\/\/doi.org\/10.1056\/NEJMp1916171.","journal-title":"N Engl J Med"},{"issue":"5","key":"1481_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328\u201335. https:\/\/doi.org\/10.2133\/dmpk.22.328.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"15","key":"1481_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2165\/00002018-200326150-00001","volume":"26","author":"C Bond","year":"2003","unstructured":"Bond C, Hannaford P. Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Saf. 2003;26(15):1065\u201374. https:\/\/doi.org\/10.2165\/00002018-200326150-00001.","journal-title":"Drug Saf"},{"issue":"7","key":"1481_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.18553\/jmcp.2018.24.7.682","volume":"24","author":"KB Sonawane","year":"2018","unstructured":"Sonawane KB, Cheng N, Hansen RA. Serious adverse drug events reported to the FDA: analysis of the FDA adverse event reporting system 2006\u20132014 database. J Manag Care Spec Pharm. 2018;24(7):682\u201390. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.682.","journal-title":"J Manag Care Spec Pharm"},{"unstructured":"Office of the Commissioner. MedWatch: the FDA safety information and adverse event reporting program. FDA. Available at: https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program. Accessed 10 Mar 2023.","key":"1481_CR20"},{"issue":"5","key":"1481_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40264-014-0155-x","volume":"37","author":"CC Freifeld","year":"2014","unstructured":"Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance: monitoring pharmaceutical products in twitter. Drug Saf. 2014;37(5):343\u201350. https:\/\/doi.org\/10.1007\/s40264-014-0155-x.","journal-title":"Drug Saf"},{"issue":"10","key":"1481_CR22","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/ajt.15398","volume":"19","author":"AD Leino","year":"2019","unstructured":"Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant. 2019;19(10):2944\u20138. https:\/\/doi.org\/10.1111\/ajt.15398.","journal-title":"Am J Transplant"},{"unstructured":"Epidiolex Label. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf. Accessed 9 Mar 2023.","key":"1481_CR23"},{"issue":"10","key":"1481_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865\u20139. https:\/\/doi.org\/10.1056\/NEJMp0911494.","journal-title":"N Engl J Med"},{"issue":"17","key":"1481_CR25","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1001\/jama.2019.14390","volume":"322","author":"AL Nobles","year":"2019","unstructured":"Nobles AL, Leas EC, Althouse BM, et al. Requests for diagnoses of sexually transmitted diseases on a social media platform. JAMA. 2019;322(17):1712. https:\/\/doi.org\/10.1001\/jama.2019.14390.","journal-title":"JAMA"},{"issue":"14","key":"1481_CR26","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1080\/10826084.2021.1972317","volume":"56","author":"AL Nobles","year":"2021","unstructured":"Nobles AL, Johnson DC, Leas EC, et al. Characterizing self-reports of self-identified patient experiences with methadone maintenance treatment on an online community during COVID-19. Subst Use Misuse. 2021;56(14):2134\u201340. https:\/\/doi.org\/10.1080\/10826084.2021.1972317.","journal-title":"Subst Use Misuse"},{"key":"1481_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-02311-8","volume-title":"Social monitoring for public health","author":"MJ Paul","year":"2017","unstructured":"Paul MJ, Dredze M. Social monitoring for public health. Springer International Publishing; 2017. https:\/\/doi.org\/10.1007\/978-3-031-02311-8."},{"issue":"1","key":"1481_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41746-018-0036-2","volume":"1","author":"JW Ayers","year":"2018","unstructured":"Ayers JW, Caputi TL, Nebeker C, Dredze M. Don\u2019t quote me: reverse identification of research participants in social media studies. NPJ Digit Med. 2018;1(1):30. https:\/\/doi.org\/10.1038\/s41746-018-0036-2.","journal-title":"NPJ Digit Med."},{"issue":"4","key":"1481_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1715163518779409","volume":"151","author":"AR Barry","year":"2018","unstructured":"Barry AR. Patients\u2019 perceptions and use of natural health products. Can Pharm J Rev Pharm Can. 2018;151(4):254\u201362. https:\/\/doi.org\/10.1177\/1715163518779409.","journal-title":"Can Pharm J Rev Pharm Can."},{"unstructured":"PROGRAF (tacrolimus) Label. Published online 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050708s052,050709s044,210115s004lbl.pdf. Accessed 18 Feb 2024.","key":"1481_CR30"},{"issue":"12","key":"1481_CR31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","volume":"33","author":"LO Hanu\u0161","year":"2016","unstructured":"Hanu\u0161 LO, Meyer SM, Mu\u00f1oz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357\u201392. https:\/\/doi.org\/10.1039\/C6NP00074F.","journal-title":"Nat Prod Rep"},{"unstructured":"Bulik B. Epidiolex rollout: $32,500 list price spurs critics as first cannabis drug hits shelves. Fierce Pharma. Available at: https:\/\/www.fiercepharma.com\/marketing\/epidiolex-launch-official-first-cbd-approved-by-fda-shelves-but-high-price-spurs-some. Accessed 9 Mar 2023.","key":"1481_CR32"},{"issue":"4","key":"1481_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12746","volume":"80","author":"S Golder","year":"2015","unstructured":"Golder S, Norman G, Loke YK. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol. 2015;80(4):878\u201388. https:\/\/doi.org\/10.1111\/bcp.12746.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1481_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/2576233","volume":"5","author":"CC Yang","year":"2014","unstructured":"Yang CC, Yang H, Jiang L. Postmarketing drug safety surveillance using publicly available health-consumer-contributed content in social media. ACM Trans Manag Inf Syst. 2014;5(1):1\u201321. https:\/\/doi.org\/10.1145\/2576233.","journal-title":"ACM Trans Manag Inf Syst"},{"doi-asserted-by":"publisher","unstructured":"Amir S, Dredze M, Ayers JW. Mental health surveillance over social media with digital cohorts. In: Proceedings of the Sixth Workshop on Computational Linguistics and Clinical Psychology. Association for Computational Linguistics; 2019. pp 114\u2013120. https:\/\/doi.org\/10.18653\/v1\/W19-3013","key":"1481_CR35","DOI":"10.18653\/v1\/W19-3013"},{"issue":"11","key":"1481_CR36","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/14740338.2018.1531847","volume":"17","author":"I Convertino","year":"2018","unstructured":"Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. Expert Opin Drug Saf. 2018;17(11):1081\u201393. https:\/\/doi.org\/10.1080\/14740338.2018.1531847.","journal-title":"Expert Opin Drug Saf"},{"issue":"6176","key":"1481_CR37","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1126\/science.1248506","volume":"343","author":"D Lazer","year":"2014","unstructured":"Lazer D, Kennedy R, King G, Vespignani A. The parable of google flu: traps in big data analysis. Science. 2014;343(6176):1203\u20135. https:\/\/doi.org\/10.1126\/science.1248506.","journal-title":"Science"},{"issue":"1","key":"1481_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1140\/epjds\/s13688-015-0054-0","volume":"4","author":"BM Althouse","year":"2015","unstructured":"Althouse BM, Scarpino SV, Meyers LA, et al. Enhancing disease surveillance with novel data streams: challenges and opportunities. EPJ Data Sci. 2015;4(1):17. https:\/\/doi.org\/10.1140\/epjds\/s13688-015-0054-0.","journal-title":"EPJ Data Sci."},{"issue":"5","key":"1481_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40264-022-01169-0","volume":"45","author":"O Kjoersvik","year":"2022","unstructured":"Kjoersvik O, Bate A. Black swan events and intelligent automation for routine safety surveillance. Drug Saf. 2022;45(5):419\u201327. https:\/\/doi.org\/10.1007\/s40264-022-01169-0.","journal-title":"Drug Saf"},{"key":"1481_CR40","doi-asserted-by":"publisher","DOI":"10.2196\/52499","volume":"26","author":"EC Leas","year":"2024","unstructured":"Leas EC, Ayers JW, Desai N, Dredze M, Hogarth M, Smith DM. Using large language models to support content analysis: a case study of ChatGPT for adverse event detection. J Med Internet Res. 2024;26: e52499. https:\/\/doi.org\/10.2196\/52499.","journal-title":"J Med Internet Res"},{"issue":"1","key":"1481_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49\u201358. https:\/\/doi.org\/10.1038\/s41591-022-02160-z.","journal-title":"Nat Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01481-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01481-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:23:36Z","timestamp":1736335416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01481-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01481-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"22 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the US FDA via the Johns Hopkins University Center of Excellence in Regulatory Science and Innovation, the Burroughs Wellcome Fund, and the National Center for Advancing Translational Sciences (grant UL1TR001442). The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matthew R. Allen, and Zechariah Zhu report no conflicts of interest that may be relevant to the contents of this study.\u00a0Gwenyth Portillo Wightman is a data scientist at Astrana Health.\u00a0Adam\u00a0Poliak reports paid consulting for Pearson Education, Inc. and was previously a paid intern for Bloomberg LP. Davey M. Smith has consulted for Linear Therapies, Model Medicines, Bayer Pharmaceuticals, Kiadis Pharmaceuticals,\u00a0Lucira,\u00a0Gilead, Red Queen Therapeutics, Hyundai and Vx Biosciences. Mark Dredze holds equity in Good Analytics and has received consulting fees from Bloomberg LP.\u00a0John W. Ayers owns equity positions in Health Watcher and Good Analytics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All analyses used Python 3.10.5, adhered to Reddit\u2019s terms and conditions, and were determined by the Johns Hopkins University human research protections program to be exempt because the study used public, non-identifiable data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Replication files are publicly available on Dataverse at\u00a0.\u00a0Individual post content\u00a0is not shared per Reddit's terms of service. Post\u00a0contents can be accessed via the Reddit API.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"Code will be made available upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MRA provided clinical context and led the study design jointly with JWA.\u00a0GPW and ZZ led the data collection, annotation, and analysis; DMS provided clinical context and contributed intellectual value to the manuscript. All authors have read and agreed to the final submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}